Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Summary
The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9262
Start Date
2026-05
Completion Date
2031-06
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
HRS9531
HRS9531 Dose 1 , subcutaneous injection
HRS9531 placebo
HRS9531 placebo Dose 1, subcutaneous injection
Locations (1)
Fuwai Hospital, CAMS&PUMC
Beijing, Beijing Municipality, China